A Double-Blind, Randomized, Placebo-Controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel 4759, 0/05% 2.5g and Dapivirine Gel 4789, 0.05% 2.5g Formulations as Compared to the Vaginal Hec-Based Universal Placebo Gel, 2.5g in Healthy HIV-Negative Women

Grant

Date/time Interval

  • April 1, 2009 - March 31, 2011
  • Total Award Amount

  • 357694.00
  • Direct Costs

  • 283884.00
  • Sponsor Award Id

  • IPM 020
  • Contributor

  • Craig Hoesley   Principal Investigator